Kaida BioPharma Appoints Co-Founder Dr. Stella K. Vnook as Chairperson of the Board [Yahoo! Finance]
Enveric Biosciences, Inc. (ENVB)
Company Research
Source: Yahoo! Finance
Company advancing KAD-101, a best-in-class, next-generation prolactin receptor antagonist, toward a Phase 1 clinical study FORT LAUDERDALE, FL, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Kaida BioPharma (“Kaida” or the “Company”), Kaida BioPharma (“Kaida” or the “Company”), a biopharmaceutical company focused on advancing targeted anti-cancer therapies for hormone-driven cancers affecting women, today announced a leadership transition appointing Dr. Stella K. Vnook, Co-Founder of the Company, as Chairperson of the Board of Directors. This appointment reflects Kaida's deliberate strategy to align Board leadership with the Company's next phase of growth as it advances into clinical development. Since co-founding Kaida, Dr. Vnook has played a central role in shaping the Company's scientific vision, strategic direction, and clinical, regulatory, and commercial roadmap, including the advancement of KAD-101, a best-in-class, next-generation prolactin receptor antagonist for the treatment of pla
Show less
Read more
Impact Snapshot
Event Time:
ENVB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ENVB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ENVB alerts
High impacting Enveric Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
ENVB
News
- Enveric Biosciences Expands Collaboration with TOTEC Pharma through Trademark License and OptionBusiness Wire
- Enveric Biosciences Announces Closing of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesBusiness Wire
- Enveric Biosciences Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesBusiness Wire
- Enveric Biosciences announces issuance of U.S. patent [Yahoo! Finance]Yahoo! Finance
- Enveric Biosciences Announces Patent IssuanceBusiness Wire
ENVB
Sec Filings
- 2/2/26 - Form SCHEDULE
- 1/28/26 - Form 8-K
- 1/28/26 - Form 424B5
- ENVB's page on the SEC website